Intra-Cellular Therapies (NASDAQ:ITCI) Now Covered by Analysts at StockNews.com

Investment analysts at StockNews.com began coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI) in a note issued to investors on Thursday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Other equities research analysts also recently issued reports about the company. Canaccord Genuity Group downgraded Intra-Cellular Therapies from a “buy” rating to a “hold” rating and upped their target price for the company from $119.00 to $132.00 in a report on Friday, January 31st. Cantor Fitzgerald reiterated a “neutral” rating and issued a $132.00 target price on shares of Intra-Cellular Therapies in a research note on Wednesday, April 2nd. Needham & Company LLC reiterated a “hold” rating on shares of Intra-Cellular Therapies in a report on Friday, February 21st. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $132.00 target price (up previously from $108.00) on shares of Intra-Cellular Therapies in a report on Wednesday, January 22nd. Finally, Mizuho cut Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and lowered their price objective for the company from $140.00 to $132.00 in a research report on Monday, February 24th. Eleven investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, Intra-Cellular Therapies presently has a consensus rating of “Hold” and a consensus price target of $109.70.

Intra-Cellular Therapies Price Performance

Shares of NASDAQ ITCI opened at $131.87 on Thursday. Intra-Cellular Therapies has a 1-year low of $64.09 and a 1-year high of $131.98. The business’s fifty day moving average price is $131.76 and its two-hundred day moving average price is $113.06. The firm has a market capitalization of $14.05 billion, a PE ratio of -151.57 and a beta of 0.69.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.08). The company had revenue of $199.22 million for the quarter, compared to analyst estimates of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. Equities research analysts expect that Intra-Cellular Therapies will post -0.64 earnings per share for the current fiscal year.

Institutional Trading of Intra-Cellular Therapies

Several large investors have recently made changes to their positions in the business. Accredited Wealth Management LLC bought a new stake in Intra-Cellular Therapies during the 4th quarter worth about $28,000. MassMutual Private Wealth & Trust FSB raised its holdings in shares of Intra-Cellular Therapies by 124.3% in the first quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 133 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in Intra-Cellular Therapies by 152.8% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 268 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 162 shares during the last quarter. SVB Wealth LLC acquired a new stake in Intra-Cellular Therapies in the 1st quarter valued at about $47,000. Finally, Longfellow Investment Management Co. LLC acquired a new position in shares of Intra-Cellular Therapies in the first quarter valued at $76,000. Institutional investors own 92.33% of the company’s stock.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.